Centogene Story

<div class='circular--portrait' style='background:#4E8BFC;color: #ffffff;font-size:4em;'>CE</div>
CNTG -- USA Stock  

USD 10.76  0.52  4.61%

Centogene Capital Expenditure is projected to increase significantly based on the last few years of reporting. The past year's Capital Expenditure was at 21 Million. The current year Net Cash Flow or Change in Cash and Cash Equivalents is expected to grow to about 34.4 M, whereas Earnings before Tax are forecasted to decline to (21 M). Centogene NV is scheduled to announce its earnings today. The next earnings report is expected on the 22nd of April 2021. Many investors are getting excited about healthcare space, let's analyze if Centogene NV fundamentals are strong enough to attract traders. We will evaluate why we are still confident in anticipation of a recovery. Centogene NV odds of distress is under 15 percent. Will the firm shareholders continue to take over in January?
Published over three months ago
View all stories for Centogene | View All Stories
Are shareholders happy with Centogene (NASDAQ:CNTG) basic indicators?
We consider Centogene somewhat reliable. Centogene NV secures Sharpe Ratio (or Efficiency) of 0.028, which signifies that the company had 0.028% of return per unit of risk over the last month. Our standpoint towards foreseeing the volatility of a stock is to use all available market data together with stock specific technical indicators that cannot be diversified away. We have found twenty-eight technical indicators for Centogene NV, which you can use to evaluate future volatility of the firm. Please confirm Centogene NV Downside Deviation of 4.49, mean deviation of 3.1, and Risk Adjusted Performance of 0.044 to double-check if the risk estimate we provide is consistent with the expected return of 0.12%.
Typically, a company's financial statements are the reports that show the financial position of the company. There are three main documents that fall into the category of financial statements. These documents include Centogene income statement, its balance sheet, and the statement of cash flows. Potential Centogene investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Centogene investors may use each financial statement separately, they are all related. The changes in Centogene's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Centogene's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.
The goal of Centogene fundamental analysis is to do accurate financial forecasts. There are several possible objectives to fundamental analysis, such as projecting of Centogene performance into the future periods or doing a reasonable stock valuation. The intrinsic value of Centogene shares is the value that is considered the true value of the share. If the intrinsic value of Centogene is higher than its market price, buying is generally recommended. If it is equal to the market price, it is recommended to hold; and if it is less than the market price, then one should sell all shares Centogene.
Please read more on our fundamental analysis page.

Are Centogene Earnings Expected to grow?

The future earnings power of Centogene involves the interaction of many company-specific, industry, and economic forces. Earnings estimates embody investors' opinions of Centogene factors such as sales growth, product demand, competitive industry environment, profit margins, and cost controls. Centogene stock prices adjust as these expectations change or are proven wrong. The main thing to remember is that equities with high expected earnings growth tend to underperform the market because it is usually difficult to meet the market's high expectations. Companies with low earnings expectations tend to do better than expected. Please use our latest analysis of Centogene expected earnings.

How Centogene utilizes its cash?

To perform a cash flow analysis of Centogene, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Centogene is receiving and how much cash it distributes out in a given period. The Centogene cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.
Centogene Net Cash Flow from Operations is projected to decrease significantly based on the last few years of reporting. The past year's Net Cash Flow from Operations was at (7 Million)

Centogene Gross Profit

Centogene Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Centogene previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Centogene Gross Profit growth over the last 10 years.
Please check Gross Profit in more details.

Detailed Perspective On Centogene

Although in the United States, the Securities and Exchange Commission has enforced strong rules to prevent insiders from engaging in insider trading, finding insiders among active shareholders of Centogene is not uncomon. Many companies such as Centogene have both institutions investors and insiders sharing the ownership. Retail investors typically buy and sell stocks in round lots of 100 shares or more. Other other hand institutional investors are known to buy and sell in block trades of 10,000 shares or more. Let's take a look at how the ownership of Centogene is distributed among investors.

Ownership Allocation

Centogene holds a total of twenty-one million eight hundred sixty thousand outstanding shares. Over half of Centogene NV outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Consequently, these institutions are subject to different rules and regulation than regular investors in Centogene. Please watch out for any change in the institutional holdings of Centogene NV as this could mean something significant has changed or about to change at the company. Please note that no matter how much assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.

Retail Investors
Retail Investors10.66

Asset Utilization

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Centogene has an asset utilization ratio of 42.88 percent. This indicates that the company is making $0.43 for each dollar of assets. An increasing asset utilization means that Centogene NV is more efficient with each dollar of assets it utilizes for everyday operations.

Current Assets
57.1 M
Assets Non Current
52.9 M
Current Assets57.14 Million46.32
Assets Non Current52.89 Million42.88
Goodwill13.32 Million10.8

How will Centogene shareholders react to the next dip?

Latest Risk Adjusted Performance is up to 0.04. Price may dip again. Centogene NV exhibits above-average semi-deviation for your current time horizon. We encourage investors to investigate Centogene NV individually to make sure intended market timing strategies and available technical indicagtors are consistent with their estimates about Centogene future systematic risk.

Our Takeaway on Centogene Investment

Although few other entities under the diagnostics & research industry are still a bit expensive, Centogene may offer a potential longer-term growth to shareholders. To summarize, as of the 16th of December 2020, our research shows that Centogene is a rather somewhat reliable investment opportunity with a low odds of financial turmoil in the next two years. From a slightly different view, the entity currently appears to be undervalued. However, our actual 30 days buy-or-sell advice on the firm is Strong Sell.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Achuva Shats do not own shares of Centogene NV. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com